Dalal Street Tower Talk

Delta Corp (Rs. 79.00) (Code: 532848) :- Big Bull Rakesh Jhunjhunwala, Rekha Jhunjhunwala and Morgan Stanley have acquired a large number of shares of this company, making it an outperformer.

EMCO (Rs. 26.00) (Code: 5040008) :- There is a lot of movement in the shares of this heavy electrical equipment maker. Promoters have increased their stake by 2%. FIIs and DIIs are also buying heavily. The company is expected to benefit from the Bihar package announced by prime minister Narendra Modi.

Shemaroo (Rs. 271.00) (Code: 538685) :- This media entertainment company has delivered good returns since entering the equity market. It plans to develop content library with an investment of Rs. 200 crores. The plan will have a positive impact on the stock

Cipla (Rs. 697.00) (Code: 500087) :- The stock had undergone sharp correction after it announced the quarterly results. However, of late, in spite of the market uncertainty and the depreciation of the rupee, traders and investors are showing a lot of interest in the stock. The stock can deliver good returns in the short term for those willing to take a risk.

Comments

Best Buy For Monday Upper Circuit Expected TCI FINANCE

*Intraday & Short Term News For Monday* *Fii And Dii News* *TCI FINANCE LTD (501242 & NSE) (31)* Incorporated in 1973, TCI Finance Ltd (TCIFL) is a Non-Banking Finance Company (NBFC) registered with the RBI and engaged in the business of Inter-Corporate Deposits, investment in equities of bodies corporate etc. The Company was promoted by Mr. Mahendra Agarwal, who is also the Managing Director and CEO of Gati Ltd, a pioneer in express distribution and supply chain and promoted by TCFIL The Rs.2 paid-up share of Gati Ltd currently trades at Rs.113. TCIFL has one subsidiary - ITAG Business Solutions Ltd engaged in the business of Knowledge Process Outsourcing (KPO) in the domain of Intellectual Property Services. *It is co-promoter of GATI LTD. Company is holding 55,12,455 shares (5.09%) stake in GATI LTD. At CMP value of investments is around Rs.62.3crore. Equity is Rs.12.87crore. Thus value of investment works out to Rs.48.4 per share ...

Danlaw Technologies India Ltd: For multi-bagger gains (BSE Code: 532329) (CMP: Rs. 60.75) (FV: Rs.10)

The earnings season so far has been weak and worries over domestic growth continue to weigh on the market sentiment which has led the markets back on the downward path.. A value investor, however, need not worry about the broad markets as value stocks perform better and post good results. One such value-pick is Danlaw Technologies India Ltd. (DTIL). Company background: DTIL is the offshore technology and product development center of its parent company - Danlaw Incorporated, founded by Mr. Raju Dandu and Mr. Lloyd Lawrence in Michigan, USA in 1984. DTIL’s mission is to provide high quality services and products in Automotive Electronics, develop R&D driven Signal Processing technologies for communication and control, configure solutions and provide exceptional Information Technology (IT) services in the areas of education, health, banking and e-governance and provide world-class products and solutions for secured access through biometric access control technologies with intellige...

Some Opportunities Are left in Pharma Sector

Torrent Pharmaceuticals reported impressive 75% growth in revenues and profit in the first quarter of FY 2016. The sterling performance was driven by the launch of new product in the US market, which has limited competition at present. The focus is on the therapeutic segments of cardiovascular and CNS. There is presence in gastro-intestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology and pediatric segments as well. The manufacturing plants for formulations and bulk drugs have been approved by authorities of several regulated and semi-regulated markets such as the US, the UK, Brazil, Germany, Australia and South Africa. Capacity will increase almost 100% once the new plant at Dahej in Gujarat becomes operational. The plant will be one of the largest pharmaceuticals manufacturing facilities in the country at a single location. The unit will primarily cater to the key regulated markets of the US and Europe. Approval from regulators such...

Value Research

Search This Blog